JOURNAL OF INTERNATIONAL CRISIS AND RISK COMMUNICATION RESEARCH
ISSN: 2576-0017
2024, VOL 7, NO S11

Emerging Threats in Medical Mycology: A Comprehensive Review of Fungal Infections and the Rise of Candida Auris

Abubakr A Almehdar[1], Mohammad Ahmad Alharbi[1], Nawaf Obaid Mutair Alenazi[2], Ayman Mousa Ahmed Almuhanna[3], Hussain Baker Alshaks[4], Salem Olayan Almaghthawi[5*], Fatimah Sami Mohammed Busaleh[6], Amjad Zaki Hassan Al Ganam[7], Naif Muteb Almutairi[8], Tahani Mohammed T Alrashidi[9], Bashayr Salem Alsenani[9], Rubayyi Mohammed Madkhali[10], Tahani Salah Mutae Aljohani[11], Hanan Sulaiman Mohammed Alhejaili[11], Abdulaziz Hudairy Alhazeemi[12]

[1]King Fahad Hospital Madinah, Madinah 42351, Saudi Arabia
[2]Al Shamli General Hospital, Hail Health Cluster, Ash Shamli 55581, Hail, Saudi Arabia
[3]Mental Health Hospital Dammam, Al Anwar, Dammam 32312, Saudi Arabia
[4]Maternity And Children Hospital, Al Muraikabat, Dammam 32253, Saudi Arabia
[5]Madinah Cardiac Center, Al Jamiah, Madinah-42351, Saudi Arabia
[6]Eradh Complex and Mental Health in Dammam, Dammam 32312, Saudi Arabia
[7]Prince Sultan Hospital-Melija, Mulayjah 37641, Saudi Arabia
[8]King Saud Hospital, Unaizah, Al Qassim 56437 Saudi Arabia
[9]Madinah Health Cluster, Ministry of Health, Madinah 42351, Saudi Arabia
[10]Al-lahien Primary Healthcare Center -Madinah, Saudi Arabia
[11]Ohud Hospital in Madinah, As Salam, 7118, Medina 42354, Saudi Arabia
[12]North Medical Tower Hospital, Ministry of Health, Arar-73241, Saudi Arabia
**Corresponding author: salem3877@gmail.com (Salem Olayan Almaghthawi)*

Abstract

Mycoses, fungal diseases are an ever-growing challenge to global health, with such a wide variety of clinical manifestations that it is difficult to count them. Most fungal species are benign though a few of them (approximately 300) can affect the human being, especially the individuals with weak immune systems like patients with cancer, members who have undergone transplants, and people with HIV/AIDS. The dramatic increase in the invasive fungal infections is directly linked with improvement of medical interventions, immunosuppressive medications and prevalence of broad-spectrum antibiotics usage. Specific attention should be reserved to Candida auris, a stream of multidrug-resistant fungal pathogens that caused outbreaks in healthcare facilities across the globe. C. auris has shown high mortality rates, resistance in multiple antifungal drugs, inability to be removed from surfaces, and common misidentification with regular diagnostics tools, which made the control and treatment of the infection difficult. Climate change, urbanization, global traveling, and agricultural overuse of antifungal medications serve as the additional factors promoting the spread of resistant fungal pathogens. Such dynamics indicate the necessity of more effective diagnostic technologies, surveillance, and new therapeutic strategies such as developing vaccines and using antifungal stewardship. This review gives a complete overview of the pathogenesis, epidemiology, diagnostic and resistance nature of fungal infections especially candidiasis, with a special emphasis on an emergent pathogen, Candida auris, its importance in putting forward the big effort as a multi-pronged approach as a great challenge in curbing or reducing the growing menace of fungal diseases.

Keywords Fungal infections; Candida auris; Multidrug resistance; Antifungal therapy; Immunocompromised patients.

Introduction

Mycoses, also called fungal infections, pose a significant and changing threat to human health and show a broad spectrum of clinical enhancement, which varies between scab togous diseases (skin and nails) and systemic invasive, life-threatening infections. Although most of the fungus species are safe to humans, there are a few species that have the capacity to cause disease; this is estimated to be approximately 300 species (Casadevall, 2022; LeÃ orthachaitaoá particularly peculiar; 2021). These virulent fungi have diverse virulence mechanisms that help them to colonize, invade and destroy the host (Angiolella, 2022). The cases of fungal infections are primarily incriminated among the immunocompromised population, such as HIV/AIDS, transplant patients, and chemotherapy patients, as they are linked to a high morbidity and mortality rate (Angiolella, 2022; Bruch et al., 2021).

Fungal infections of humans are vast, ranging through superficial or cutaneous, subcutaneous, and systemic mycoses, which are, however, characterized by the body part affected and the identifying fungus species (Melo et al., 2017). Superficial mycoses like pityriasis versicolor belong to the skin and hair and superficial tissues; whereas, cutaneous mycoses, e.g., dermatophytoses (athlete foot, ringworm), penetrate keratinized skin, hair, and nail tissue. Subcutaneous mycoses Include deeper layers of the skin and subcutaneous tissues such as sporotrichosis which are often caused by traumatic inoculation of fungal spores. The most serious fungal infection is the systemic mycosis, which are aspergillosis, candidiasis and cryptococcosis, which attack internal body organs and spread through the body (Srinivasan et al., 2014).

Cases of invasive fungus infections have rapidly grown over the last several decades due to a variety of factors, one of the most significant being a rise in the number of immunocompromised patients, with other factors being an availability of broad-spectrum antibiotics and an access to more procedure-based care (Retanal et al., 2021). It is worth noting that the increased prevalence of invasive fungal diseases may be explained by the high number of patients with HIV/AIDS, namely in the African continent, as well as the spread of treatment using immunosuppressants across the globe and the development of multi-drug resistant fungi (Hou et al., 2024; "Journal of Mycology and Infection," 2018).

The fungal pathogens are opportunistic pathogens that in healthy people do not result in the disease but cause infections that are life-threatening among immunocompromised patients (Drummond et al., 2014). With improvement in medical interventions on individuals living with cancer, autoimmune diseases, HIV, solid or stem cell transplants or invasive devices, life expectancy of individuals has increased and been enhanced, however, has also contributed to increased susceptibility to severe fungal infections in such individuals (Lino et al., 2024).

Introduction to Candida auris as a case study

Candida auris is one of the newly discovered multidrug-resistant pathogenic fungi that has proved to be of great concern to global health. It represents a high-threat to human health globally because it is hard to be diagnosed with a standard laboratory method and acquires in some forms resistance to any type of antifungal medication that is often used to fight Candida infections (Hetta et al., 2023). It was initially discovered in 2009 in Japan and has since then spread at a rapid rate all around the world where it was an outbreak inside healthcare facilities and plagued vulnerable patients (Wang et al., 2022).

The diseases related to C. auris are especially dangerous and are mostly dangerous to people who have a low immunity system and are in hospitals (Brown, 2011). That can be explained by antifungal resistance, misidentification, and the potential to continuously colonize hospitals (Jong & Hagen, 2019). The immediate and correct identification of patients infected with C. auris, its susceptibility profile detection, and the correct application of infection control precaution methods represents essential steps in limiting the infection spread of this pathogenic yeast in healthcare facilities and outbreak prevention (Ahmad & Asadzadeh, 2023). In comparison with other Candida species, C. auris demonstrates an excellent skill to be transmitted among people (Jong & Hagen, 2019).

Susceptibility and immunocompromised States

The immunocompromised are people with weak immune systems and have an increased risk of contracting a vast number of infections, including those attributed to opportunistic fungi. Compared to the general population, these persons, who are often seen in healthcare facilities, including in the intensive care units or transplant centers, are at high risk of acquiring severe and invasive fungal diseases, which may cause a heavy level of morbidity and mortality (Mallick et al., 2025)

Immunocompromised states include varieties of conditions and factors which derail the usual operations of the immune system leaving individuals susceptible to infections. These states may be caused by a number of factors that include: defective development or functioning of immune cells that may be genetically incurred, acquired immunodeficiency syndrome disease (AIDS) which is caused by HIV infection, immunosuppressant drugs taken to prevent rejection of transplanted organ or treatment of autoimmune disorders, cancer related drugs e.g. chemotherapy and radiation therapy to treat cancer patients, cancer treatment, and chronic diseases e.g. diabetes, and poor nutrition that debilitate the immune system over time. With these groups, the immune system of the body has become weakened, and pathogenic fungi can become well-established with severe illness (Harun et al., 2019).

Table 1: Classification and Examples of Human Fungal Infections.

Type of Mycosis	Affected Area	Examples	Causative Agents	References
Superficial Mycoses	Outer skin/hair	Pityriasis versicolor	Malassezia furfur	Melo et al., 2017
Cutaneous Mycoses	Skin, nails, hair	Athlete’s foot, ringworm	Trichophyton, Epidermophyton, Microsporum	Melo et al., 2017
Subcutaneous Mycoses	Dermis, subcutaneous tissue	Sporotrichosis	Sporothrix schenckii	Melo et al., 2017
Systemic Mycoses	Internal organs	Candidiasis, aspergillosis, cryptococcosis	Candida spp., Aspergillus fumigatus, Cryptococcus gattii	Srinivasan et al., 2014

Immune system mechanisms against fungal infections

The immune system uses many different ways of protecting against fungal infection, which include: Recognition of fungus-specific molecules by pattern recognition receptors on immune cells, which simulates downstream signaling pathways that activate antifungal immune responses (Lionakis et al., 2023). Phagocytic cells like macrophages and neutrophils ingest and kill fungal cells in the process of phagocytosis. Lymphocytes T, such as CD4+ and CD8+ cytotoxic T cell, have a great responsibility in the proportioning of the antifungal immunity responses and destruction of infected cells. Signaling molecules are cytokines like interferon-gamma and interleukin-17 that control the homeostasis of an immune cell and lead to an antifungal immune response (Ruchti & LeibundGut-Landmann, 2022).

These defense mechanisms are overwhelmed when the immune system is weak leaving an individual at risk of infections with opportunistic fungi. Patients who are immunocompromised focus on the risks of developing invasive fungal infections because they have low immune defenses (Riley, 2021). With these people, the equilibrium between the immune system of the host and the fungal pathogen becomes worn and the fungus gains an opportunity to multiply and become spread across the body (Lamps et al., 2014). Emerging fungal pathogens are novel or more dominant fungi that threaten the well-being of humans (Groll & Walsh, 2001). Emerging infectious disease An emergent disease is a new disease in a population or one that recently has been growing rapidly in incidence or geographic distribution. It is not difficult to see that the main challenge is the prevalence of low-quality sick leaves (Harun et al., 2019).

The role of fungal pathogen emergence is complex and is facilitated by the following factors: Fungal pathogens may become established and spread to new geographical locations due to human demographic and behavioral changes, including the renewed international travel and urbanisation trends (Loh & Lam, 2023). Use of medical innovations e.g. organ transplantation and use of immunosuppressive drugs have further broadened the group of immunocompromised patients who develop fungal infections (Lino et al., 2024). There are some alarming fungal pathogens, such as Candida auris, that has become multidrug-resistant and an outbreak in healthcare facilities; Aspergillus fumigatus, a commonly encountered mold capable of causing invasive infections when it enters the body of an immunocompromised patient; and Cryptococcus gattii which rarely causes fungal meningitis in the otherwise-healthy individual. The newer list of fungi whose species have been found to be infective to humans is increasingly getting larger and this is partly as a result of employing the molecular instruments to pin identify the species (Chabasse et al., 2009). Most of these fungi are resistant to various antifungal drugs and this has caused treatment failure and further death rates.

Geographic location and spread of the emerging fungal pathogens have to do with a number of factors which include climate change, globalization and human activities. Climate change may also change the geographic area of fungus species occurrence and provide new chances of human infection. The spread of fungal pathogens across borders is promoted by globalization and the overall growth in international travel, however, human practices or activities, including deforestation and urbanization can alter the balance of ecosystems in favor of exposing humanity to fungi (Jafarlou, 2024). Fast environmental and climatic changes, and the growing mobility of people have helped infectious fungus propagation to other areas. These processes lead to the change in geographical distribution of the fungal diseases as well as appearance of drug-resistant pathogens (Jafarlou, 2024; Lino et al., 2024).

Focus on multidrug resistance and environmental persistence

The fungi may acquire resistance against the antifungal drugs by a number of ways such as: Modifications to the drug target making it less susceptible to the antifungal agent, An increment in the expression of the enzymes that destroy the antifungal agent, An intensification in the expression of efflux pumps to extricate the antifungal agent out of the fungal cell, and The creation of biofilm to safeguard fungal cells against the impact of antifungal agent. The climate change crisis and globalized transports are some of the issues that contribute to the adaptation of fungi to the rising temperatures and geographical expansions (Ball et al., 2020).

Resistance in azole antifungals has been reported in certain fungal species which is believed to have come due to its large use in medicine as well as agriculture. These forces can occur as spontaneous mutations, horizontal transfer of genes or adaptive measures on environmental stress. Plasmid-mediated resistance transfer is not known to occur in fungi but fungus organisms can develop antifungal resistance and tolerance rapidly, frequently via activation of protective stress response pathways, and in some cases involving acquisition of aneuploidy or other copy number variation (Gow et al., 2022). The environmental factors of resistance Environmental factors Environmental factors contribute to resistance Environmental factors contributing to the resistance Environmental factors contributing to resistance. The risk factors include exposure to antifungal agents when in agricultural and medical conditions; antifungal-resistant development and transmission can be increased through environmental conditions (Islam et al., 2024).

The antifungal agents' dose and the spectrum of action are also key players in development of fungi resistance (Srinivasan et al., 2014). The probability of resistance evolving due to genetic modifications requires the population size, the rate of cell advancement, the number of resistance pathways, and the damage of fitness costs to the number of every resistance pathway (Fisher et al., 2022). Moreover, multidrug resistance among Aspergillus fumigatus has been identified when infected when exposed to some antifungals that are used in agriculture, thereby illustrating the mutual dependence of human and environmental health. Efflux pumps are prevalent mechanisms by which azole resistance occurs in the

Candida, whereas, in A. fumigatus, both target site mutations and elevated copy numbers of the target gene are frequently involved (Denning, 2022).

Epidemiology and discovery

Candida auris is a multidrug-resistant yeast and it has become an international threat to societal health (Beardsley et al., 2018). C. auris was initially discovered in Japan in 2009 but later has spread fast into the care centers in various parts of the world (Kim et al., 2024). This pathogen is highly pathogenic as it is resistant to various antifungal medications, remains persistent in medical institutions, and predisposes outbreaks (AlJindan et al., 2020). The fact that it was a virulent pathogen in humans on three continents nearly at the same time, and it has strong pathogenicity in humans along with other experimental animal models raises the issue of the origin of the pathogen (García-Bustos et al., 2021). In Europe, the initial hospital-related outbreak was described in 2016 in a cardio-thoracic center in London, the UK, where 50 cases of C. auris were diagnosed between April 2015 and July 2016 (Stanciu et al., 2023).

The fungus is long-lasting on patient skin and on the mucus membranes of the patients and in the hospital setting, highly transmissible, and capable of producing severe systemic infections in predisposed patients (Stanciu et al., 2023). Transmission and Pathogenicity Pathogenicity Pathogenicity is defined as the capacity of an asexual competent strain of a pathogenic agent to cause disease in a host. Candida auris has many virulence factors which make it pathogenic. Those would be its biofilm formation, attachment to the surface, and enzyme production, which is harmful to the tissue of the host (Watkins et al., 2022). C. auris develops biofilms on both the equipment used in healthcare facilities and the surfaces in such facilities, which is another factor predisposing it to existence in a healthcare facility and raising the risk of transmission.

Transmission routes

The Candida links or infection mainly can be spread by direct contact to colonized/infected persons or by contact with potentially infected surfaces or equipment. The yeast is able to colonize the skin and mucous membranes and infect wounds or cause candidemia and infections with penetration of one or multiple organs (LpezVilella et al., 2018). Healthcare facilities are one of the settings where C. auris may spread due to poor hygiene standards and insufficient cleaning of the environment (Jain et al., 2022). Acquisition C. auris is comparatively simple, especially when patients are confined in intensive care units with multiple comorbidities, because the patients are in open contact with infected patients with C. auris, the environment, or the equipment used on the patients with the colonized diseases, which can result in fatal outcomes in hospitalized patients with C. auris (Ahmad & Alfouzan, 2021). Such places as intensive care units and the ones when the patient has a dire illness and invasive work is inevitable are deemed high-risk transmission areas (Arthisari et al., 2023).

Table 2: Mechanisms of Antifungal Resistance in Candida auris.

Mechanism	Description	Clinical Impact	References
Efflux Pump Overexpression	Pumps antifungal agents out of the fungal cell	Reduces intracellular drug concentration	Denning, 2022; Gow et al., 2022
Drug Target Mutations	Mutations in genes like ERG11 affecting azole binding	Reduced drug binding affinity	AlJindan et al., 2020
Biofilm Formation	Protects fungal cells from drug penetration	Increased resistance in catheter-related infections	Ahmad & Alfouzan, 2021
Aneuploidy and Gene Copy Number Variation	Increases expression of resistance genes	Enhances tolerance under drug pressure	Gow et al., 2022

Clinical Manifestations

Candida auris may impose adverse outcomes on the health of patients due to systemic infection (Yune et al., 2023). Individuals with more than one health risk aspect are also highly vulnerable to dying once infected (Bhargava et al., 2025). The invasion by C. auris has very high rates of mortality (Yune et al., 2023). Cases of C. auris causing mortality may be challenging as majority of patients who die following the development of invasive infection have severe underlying conditions. Candidemia is the rapid growth of C. auris that affects the internal organs through the systemic blood infection process and results in the 30-70 percent crude mortality rate (Sanyaolu et al., 2022).

Invasive ones that can be caused by C. auris colonization occur in about 10 percent of patients with mechanical ventilation and invasive devices associated with high risks (Ahmad & Alfouzan, 2021). It underscores the significance of the swift and precise diagnosis of C. auris to support the proper treatment and infection control processes (Ahmad & Alfouzan, 2021; Arthisari et al., 2023). Candida auris is a common cause of the bloodstream infections (candidemia), which may result in sepsis and septic shock. The most frequently noted invasive infection is bloodstream infection, and the rate of death in the hospital is on the same level or up to 30-60%. (Spivak & Hanson, 2017). The fungus may enter the bloodstream via different ways, among them are infected prostheses, central catheters, the skin, or mucous membranes being punctured. C. auris is a common parasite that weakened immune systems carriers (i.e. persons who received chemotherapy, an organ transplant, etc.) are especially susceptible to (Lopez-Villella et al., 2018).

Diagnostic and symptom complexes

Symptoms of C. auris infection may be different: they depend on the location of the infection and the health conditions of individuals. C. auris infection produces a certain clinical presentation that directly relates to the infection location (Sticchi et al., 2023). The clinical manifestation that is most prevalent is candidemia. C. auris infection often produces non-specific symptoms, which are similar to other types of infections; it can be hard to diagnose it. The organism is also halotolerant due to the colonization of C. auris on the skin, especially axilla and groin, which are the parts that may be under high salinity and temperature predisposition in the case of strenuous physical activity (Gaetano et al., 2024). C. auris might be misidentified by the traditional microbiological procedures, and this factor contributes to slow diagnosis and treatment (Watkins et al., 2022).

Antifungal Resistance

Also, the ability to resist various antifungal drugs is one of the most alarming peculiarities of C. auris. These also involve an opposition to often used azoles, echinocandins, and polyenes, reducing the amount of treatment, and leading to a higher chance of treatment failure (Bhargava et al., 2025). Another peculiar feature of C. auris is its capacity to spread biofilms and aggregative Hs, which can hardly be removal (Ahmad & Alfouzan, 2021). Arguably, there is resistance to azoles, echinocandins and amphotericin B. Drug-resistance strains of C. auris are related to more severe infections with hospitalization and a high number of deaths (Arthisari et al., 2023).

Misidentification in clinical laboratories C. auris has been of major concern, at least during the first years following its detection. This has contributed to delayed diagnoses, improper treatment and outbreaks not being traced (Du et al., 2020). The cases of identification difficulties in the laboratory are explained by the fact that C. auris has unusual growth habits and cell shapes, which makes them in many cases incorrectly identified through traditional methods as other more widespread species of Candida (Bassey et al., 2016). The appearance of C. auris was valuable related to the laboratory-based detection (Giacobbe et al., 2023). Molecular diagnostic and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry have helped enhance the accuracy and the time of identifying C. auris in clinical laboratories (Sigera et al., 2020). Some of the causes which have led to its rise real late include growth in international travel and the difficulty of identifying it in a laboratory (Boutin & Luong, 2024).

Environmental Stability and Transmission

Its environmental persistence, which plays a significant role in its transmission and propagation since the species can remain on hospital surfaces within the environment over a long time (Sabino et al., 2020). It may survive a couple of weeks on surfaces, which adds to its spread in healthcare facilities (Geremia et al., 2023). This heartiness allows colonization of the hospital rooms, and medical devices, resulting in outbreaks in healthcare centers. C. auris outbreaks have been reported in several countries, which proves its ability to invade healthcare institutions (Mallick et al., 2025). Europe The first reported hospital outbreak in the context of C.auris occurred in 2016 in an UK-based cardio-thoracic center, where 50 cases of C.auris infections were recorded between April 2015 and July 2016 (Stanciu et al., 2023).

C. auris is a concern of Centers for Disease Control and Prevention in the United States (CDC). It is an emerging fungus, and a dangerous risk to world health (Benedict et al., 2023). The World Health Organization has indicated C. auris as a priority that requires a comprehensive amount of research and/or efforts in the field of public health to restrict its dissemination (Benedict et al., 2023; Du et al., 2020; Sticchi et al., 2023). C. auris colonizes the human skin preferentially as opposed to the other Candida species, which include Candida albicans, contributing to a nosocomial spread and outbreak of systemic fungal infection (Balakumar et al., 2024). The swift geographical dispersion of C. auris and its tendency toward the drug resistance have become an issue of concern among medical practitioners and health state organizations (Das et al., 2025).

Diagnosis and Treatment Challenges

C. auris may not be properly identified using conventional microbiological techniques, and instead of immediate treatment, it might take for some time to diagnose it. It may cause delayed diagnosis, ineffective treatment of medical workers and the possibility of the spread of an outbreak undetected (Hu et al., 2021). Traditional techniques are not so successful in C. auris identification because it may be confused with other Candida species easily (Gaetano et al., 2024). It underlines there is a necessity of more accurate diagnostic tools. The emergence of antifungal resistance to C. auris has made it difficult to select effective antifungal treatment. The increasing levels of antifungal resistance detected in the C. auris isolates produce a substantial barrier to the effective clinical care that frequently leads to the involvement of multidrug therapy or, in the most tenacious cases, leads to therapeutic intractability. Antifungal therapy is not endowed with specific guidelines and therefore it is hard to achieve informed antifungal treatment by the clinicians. Lack of conclusive treatment principles may further bring about delayed response time of target intervention applications, often forcing healthcare providers to undertake empirical procedures of treatment that may fail to work well with the available strain of C. auris. This is because they have strong personalities and not because they are stars (Griffith & Danziger, 2020).

Drug resistance: implications for treatment success

Drug-resistant infections of C. auris are linked to a higher rate of mortality and increase of length of stay (Eix & Nett, 2024). Resistance emergence is a significant barrier to treatment success and in many cases, combination therapy must be used or experimental treatment should be applied (Kean et al., 2020). Up to 50% percent of C. auris clinical isolates are claimed to be resistant to amphotericin B but the ways contribution to this resistance have not been determined yet (Rybak et al., 2021). Resistance among C. auris is acquired by different ways such as the modification of target sites, amplification of efflux pumps, and the ability to form biofilms. One of the saddest issues is a rapid development of multidrug-resistant isolates that would appear as a result of antifungal treatment (Giacobbe et al., 2023). About half of the C. auris isolates of several studies were showing resistance to fluconazole, then amphotericin B, and another antifungal medication (voriconazole, caspofungin and flucytosine) (Bandara & Samaranayake, 2022).

The recent appearance of C. auris raises the necessity of quick and precise diagnostic tools in order to detect the organism and ascertain its vulnerability regarding antifungal medications. Such tests may assist in making the right treatment and help prevent infections (Mishra et al., 2023). To guide the treatment, it is necessary to conduct susceptibility tests and monitor the onset of resistance. The problem of antifungal susceptibility to the disease should be solved through rapid and precise diagnostics to provide adequate decisions to treat infected people and prevent the progression of infection to the population (Posteraro et al., 2014). It is of high priority that C. auris isolates undergo antifungal susceptibility testing to avoid treatment failures and provide better patient outcomes.

Innovation of treatment methods and drug production

Because of the limitations attributed to the existing antifungal drugs, it is important to explore and express novel treatment options. Development of new antifungal treatment and new therapies is required to fight the C. auris post-infections. Shortage of licensed treatment has been among the main obstacles to effective parasite control in aquaculture (Shinn & Bron, 2012). Since the available repertoire of effective antifungal agents is limited, and there is the risk of developing resistant C. auris, new treatment methods are urgently needed, and they can involve the discovery of a new generation of antifungal drugs, adaptation of older ones to other uses, and the search of alternative treatment methods including immunotherapy and phage therapy. Of possible alternatives, combination therapies have also been suggested which can be used in the continuation or recurrence of infections, including flucytosine and amphotericin B bladder irrigations (Griffith & Danziger, 2020).

Strategies of Control and Prevention

C. auris is a very dangerous organism, and so its actual diagnosis and protection management is complicated right now. Preventative infection control measures or strict hand hygiene, environmental, and patient isolation in healthcare facilities will be important to curb the spread of C. auris infection (Hayes, 2024). The prompt case identification of C. auris with a rapid response through strict surveillance of infection control (i.e., hand hygiene, environmental hygiene, and isolation of infected patients) is vital to prevent nosocomial infections and outbreaks. Halili and Sorensen (2020) argued that big data may be deterred by resistance and dominated by hierarchical relations as well as hegemonic.

Table 3: Risk Factors and Clinical Challenges Associated with Candida auris.

Category	Details	References
Major Risk Factors	ICU admission, mechanical ventilation, immunocompromised state, broad-spectrum antibiotics usage	Ahmad & Alfouzan, 2021; Mallick et al., 2025
Clinical Challenges	High mortality (30–70%), misidentification, delayed diagnosis	Spivak & Hanson, 2017; Yune et al., 2023
Diagnostic Limitations	Misidentification with C. haemulonii, limited sensitivity of conventional methods	Du et al., 2020; Watkins et al., 2022
Environmental Persistence	Survives on surfaces for weeks, contributes to outbreaks in hospitals	Sabino et al., 2020; Geremia et al., 2023

Public Health and Implications of Infection Control

The spread of C. auris can be prevented by early detection and vanguard of cases. Screening can be used to detect colonized people, through the use of screening programmes, so as to curb further transmission. Vigilant screening programs can be associated with immediate identification of colonized persons, which in turn allows to implement more specific infection control procedures and prevent additional ones (Hayes, 2024). Hyper vigilance use of infection prevention and control interventions is a major factor in the management and prevention of C. auris transmission (Halili & Sorensen, 2020). A proper disinfection of the environment is necessary to eradicate the C. auris on surfaces. Requisite cleaning measures as well as the use of suitable disinfectants play a fundamental role in effective environmental decontamination (Shinn & Bron, 2012).

Along with the proper care about environmental disinfection, sterile compliance with hand hygiene measures proves to be one of the main pillars of efficient infection control interventions. Cleaning and disinfection of environmental surfaces with proper antimicrobial agents should be practiced in depth to lower the environmental burden of C. auris. In patient care regions, special involvement must be directed to often operated surfaces and equipment (Sathyapalan et al., 2021). Little is known about the total numbers of cases on the ground, but it is believed that environmental disinfection is important in averting transmission of this emerging pathogen (Lucy et al., 2022). Skin disinfection and duhum cleansing is believed to be the optimal solution to minimization of the transmission (Omardien & Teska, 2024). Body-wash chlorhexidine, octenidine wipes and mouth wash are effective (Sathyapalan et al., 2021). The significance of infection control as a measure against the spread of C. auris has been stressed (Moore et al., 2022).

Surveillance system importance

Observation mechanisms are an essential aspect to track the appearance and the growth of C. auris. The priority should be to put in place effective surveillance facilities to keep track of the occurrence and transmission of C. auris. Such systems can contribute to the monitoring of the infections frequency, the risk factors and the control measures efficacy. Surveillance systems allow healthcare centers and public health agencies to respond to out of control infections by measuring the rate of infections and patterns and take targeted measures to control the scale of the infection. Healthcare-associated infections surveillance should occur to enhance patient outcomes (Sansom et al., 2022). One of the most appropriate methods of decreasing the rate of hospital infections is surveillance (Mandal et al., 2021).

The healthcare workers can help to prevent the spread of C. auris by respecting the infection control guidelines and teaching the patients and their families (Blackman et al., 2021). Ignorance on the side of healthcare professionals is one of the biggest problematic issues in the spread of infection prevention (Hennessee et al., 2024). They should also know the signs and symptoms of C. auris infection and the necessary measures they must take in tooid its transmission. Healthcare facilities, policymakers, and public health agencies should cooperate in order to elaborate and carry on extensive measures to prevent and control C. auris infections (Yune et al., 2023). Population-based health protection and enhancement cannot be achieved without the use of public health policies. Its policy-makers are required to pay attention to numerous issues, such as scientific evidences, while making public health policies. The area of public health policy is important when it comes to solving many health issues (Sathyapalan et al., 2021).

C. auris has led to the introduction of a new risk of multidrug-resistant fungus pathogen, Candida auris (C. auris), which has been a great challenge to global public health (Sanyaolu et al., 2022). A swift spread level in healthcare facilities along with significant death rates related to invasive infections requires an in-depth knowledge of its epidemiology, clinical presentation, and effective control methods (Yune et al., 2023). Active surveillance procedures to diagnose the C. auris in critical care units were one of the offered components of infection control policy in hospitals (Mirabet et al., 2020). Regular cultures of active surveillance may help to detect the C. auris colonization early, which will be used to introduce infection control measures on time to prevent outbreaks (Mirabet et al., 2020). Due to the possibility of the occurrence of transmission of C. auris via donor during a transplant, a careful screening of the possible donor is essential (Azar et al., 2017).

Research requirements and future directions

New antifungal drugs should also be developed urgently to fight infections caused by C. auris. In the future, the mechanistic details of its biology, epidemiology, antifungal resistance, and pathogenesis must be understood with an aim to develop new tools and techniques of preventing, diagnosing, and treating C. auris infections (Du et al., 2020). New drug targets and the development of new diseases with enhanced anti-fungal properties should be conducted to make a breakthrough. Wholesale treatment of invasive fungal diseases is still a tremendous issue and there is an urgent necessity of new antifungal treatments (Citarasu, 2009). Genomics approach to the detection of resistance genes has been established to be a viable and precise means of determining resistance phenotypes. The management of antimicrobial resistance is useful thanks to the characteristics of genomics to identify the various genes of resistance all together. Use of genomics in surveillance of antimicrobial resistance assists in detection of new patterns of resistance and to provide optimal use of antimicrobials. More studies should be done to investigate the mechanism of the antifungal resistance of C. auris. All these perfectly fit into the definition of that which is commonly referred to as a 5-year project in everyday language (Kim et al., 2024).

Diagnostic advances

Diagnostic tests are very necessary in order to identify C. auris infections in good time and most importantly; the tests ought to be rapid and accurate. The development of novel molecular-based tests (PCR and next-generation sequencing) to diagnose C. auris has potential and could enhance the accuracy and reduction of time consumption in the diagnosis of C. auris. Creating quick and precise tests to diagnose C. auris has proven to be critical to the early detection and adequate treatment of infections (Hata et al., 2019). There is a need of continuous research to streamline the measures used to combat the control of infections to avoid outbreak of the infection by C. auris. This also involves testing the efficiency of various disinfection procedures and determining new strategies of decontaminating the environment. In the future, it would be necessary to research the effectiveness of various measures to combat infections, including hand hygiene, environmental decontamination, and patient isolation, and the prevention of C. auris (Tu et al., 2022).

The modifications, including nanoparticles, drug repurposing, and the use of natural products, are also considered to have a life-saving effect and decreased resistance (Billamboz et al., 2021; Niño-Vega et al., 2024). During the past decades, fungal infections have been experiencing an increasing rate, which poses a severe hazard on the global population (Cernakova et al., 2021). The reason is the problem of antimicrobial resistance, and the smaller number of classes of drugs than in bacterial diseases (Černakhova et al., 2021). The increase in fungal infections, which are complicated by viral ones, as well as the discovery of new forms of fungus in tumors and the appearance of new fungal pathogens, testifies to the pressing nature of the problem (Wang et al., 2025). The emerging multidrug-resistant fungal pathogen Candida auris (C. auris) has become a worldwide emerging global fungal pathogen that has raised lots of concerns in the medical field and the world at large (Jong & Hagen, 2019). First detected in Japan in 2009, C. auris has continued its spread around the world, resulting in nosocomical outbreaks of unacceptable mortality (S. Wang et al., 2023; Y. Wang et al., 2022). It can be easily transmitted in healthcare facilities, dawdle a long time, infect the skin and survive on an inorganic surfaces (Kappel et al., 2024). What also complicates the situation is its ability to be resistant to significant antifungal drugs, making it highly problematic when it comes to the treatment and the necessity to introduce new treatment options (Hetta et al., 2023).

These commensal fungi present an even higher risk of tissue and blood colonization and development of invasive diseases due to the rise in the application of invasive medical procedures and devices (Hetta et al., 2023). The challenges of precisely diagnosing C. auris and its low diagnostic yield when standard laboratory testing tools and protocols are used further add to the issues of properly evaluating the prevalence of the pathogen and taking proper, effective infection control precautions (Ahmad & Asadzadeh, 2023). There is a need to enhance already existing anti-infection measures and develop innovative verticals to prevent the transmission of C. auris in the healthcare environment. It has been produced in different parts of the body such as in the aural canal, urine as well as the respiratory system. The spread of the isolate in the hospital was brought under control by satisfactory infection control measures, even though the source of isolate could not be located (Kurt et al., 2021).

The idea of vaccination has a huge potential of preventing fungal infections, especially among vulnerable groups. The improvements of immunology and the new types of vaccine platforms contributed to the creation of potential vaccine candidates against fungal diseases. However, it has several challenges regarding the creation of effective and sustainable vaccines against fungal diseases. Development of vaccines against fungus to provide protective immunity a prospective strategy in prevention of life-threatening fungal infections in people at risks is developing fungal vaccines targeting conserved antigens. There is a need to carry out intensive preclinical and clinical trials to ascertain the safety, immunogenicity and effectiveness of such vaccine candidates. There are various studies being undertaken to create vaccines that would be used to retain protection against C.auris and other fungal infections (Burgess et al., 2022; Casadevall, 2018; Harun et al., 2019; Lionakis et al., 2023). Role of climate change and environment in emerging fungal threats

Environmental aspects and climate change are becoming more accepted as possible causes and predictors of the new fungal menace. The redistribution and virulence of fungi can be modified by alterations in temperature, humidity, and other environmental circumstances, resulting in the development of new fungus pathogens and the transmission of those ones that already exist (Sabino et al., 2020). These factors may widen the geographical distribution of pathogenic fungi and introduce people to new, potentially more virulent, or drug-resistant organisms (George et al., 2025). One should remember that the threat of fungus may also be increased by natural disasters that displace people and rupture infrastructure as well as provide a perfect breeding environment of fungi. Current research regarding the linkages between environmental factors, fungal spread, and pathogen emergence is needed so that the dangers of fungal infection can be understood and mitigated. In addition, large-scale application of azole antifungals in the agricultural sector could accelerate the resistance of fungi, and this again would pose a greater threat to the health of humans (Money, 2024).

The migration of plant pathogens beyond its geographical distribution is occurring due to globalization and international trade whereby they adapt to the new climate and environmental fitness, and the existence of modern farming practices such as a shift in land use and the vast use of antifungal chemicals (Islam et al., 2024). Fungal infections also appear and circulate because of human activity (Jafarlou, 2024). Loss of forests, urban growth and agricultural activities have the potential of interfering with the functioning of ecosystems and creating more exposure of people to fungi (Jafarlou, 2024). The upheavals have the ability to open new ecological space where fungi are able to adapt and thrive. Due to climate change, fungal plant pathogens are emerging, and they become an increasingly significant threat to the global food supply (Seidel et al., 2024).

Conclusion

The problem of fungal infections, especially infections with opportunistic and drug-resistant fungal pathogens, such as Candida auris, has become a strong and increasing challenge to health care systems across the globe. The emerging epidemic of systemic fungal infections is influenced by more than the simple expansion of immunocompromised groups; it also represents a more general expansion of environmental and human factors (through global travel and changes in the climate as well as excessive use of antifungal compounds in medicine and agriculture). The dimension of Candida auris as a potentially fatal health problem across the globe is defined by its high mortality rates, habitability in the conditions of hospitals, resistance to the majority of antifungal medicines, and the problems of diagnosis. The effects of a late diagnosis, poor treatment and related infection controls may be disastrous and particularly in intensive care conditions. In order to counter this growing menace, there is need to tackle it through an integrated effort. Among these is enhancing the laboratory infrastructure on early and accurate detection, strict infection control procedures, enhancing the surveillance networks and encouraging research on novel antifungal therapy and vaccines. It is also essential to train healthcare workers, to reform the current policies, and to make people aware of the dangers to minimize the spread of the disease and to have better results in treatment. Fungal pathogens are evolving and hence, our scientific, clinical, and population health approaches to foresee, identify and resolve such infections within the next several decades should also be evolving.

Acknowledgement

The authors express their gratitude to the publicly accessible online library resources that aided them in conducting an exhaustive literature assessment. Lastly, the authors really appreciate the corresponding author's informative remarks, which greatly improved the manuscript's quality.

Author contributions

Although the first author wrote the manuscript's original text, all writers made substantial contributions through data collecting and literature searches. Each author pledged to accept complete responsibility for the work by taking part in the critical revision of the manuscript and approving the final draft.

Conflict of Interest

Authors declare they don’t have any conflict of interest.

Ethical Approval

Not Applicable

References

1. Ahmad, S., & Alfouzan, W. (2021). Candida auris: Epidemiology, Diagnosis, Pathogenesis, Antifungal Susceptibility, and Infection Control Measures to Combat the Spread of Infections in Healthcare Facilities [Review of Candida auris: Epidemiology, Diagnosis, Pathogenesis, Antifungal Susceptibility, and Infection Control Measures to Combat the Spread of Infections in Healthcare Facilities]. Microorganisms, 9(4), 807. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/microorganisms9040807
2. Ahmad, S., & Asadzadeh, M. (2023). Strategies to Prevent Transmission of Candida auris in Healthcare Settings [Review of Strategies to Prevent Transmission of Candida auris in Healthcare Settings]. Current Fungal Infection Reports, 17(1), 36. Springer Science+Business Media. https://doi.org/10.1007/s12281-023-00451-7
3. AlJindan, R., AlEraky, D. M., Mahmoud, N., Abdalhamid, B., Almustafa, M., AbdulAzeez, S., & Borgio, J. F. (2020). Drug Resistance-Associated Mutations in ERG11 of Multidrug-Resistant Candida auris in a Tertiary Care Hospital of Eastern Saudi Arabia. Journal of Fungi, 7(1), 18. https://doi.org/10.3390/jof7010018
4. Angiolella, L. (2022). Virulence Regulation and Drug-Resistance Mechanism of Fungal Infection. Microorganisms, 10(2), 409. https://doi.org/10.3390/microorganisms10020409
5. Arthisari, N. N. N., Budayanti, N. N. S., & Tarini, N. M. A. (2023). Candida auris as a pathogen that can cause emerging infectious disease: a literature review [Review of Candida auris as a pathogen that can cause emerging infectious disease: a literature review]. Intisari Sains Medis, 14(1), 394. Udayana University. https://doi.org/10.15562/ism.v14i1.1679
6. Azar, M. M., Turbett, S. E., Fishman, J. A., & Pierce, V. (2017). Donor-Derived Transmission of Candida auris During Lung Transplantation. Clinical Infectious Diseases, 65(6), 1040. https://doi.org/10.1093/cid/cix460
7. Balakumar, A., Das, D., Datta, A., Mishra, A., Bryak, G., Ganesh, S. M., Netea, M. G., Kumar, V., Lionakis, M. S., Arora, D., Thimmapuram, J., & Thangamani, S. (2024). Single-cell transcriptomics unveils skin cell specific antifungal immune responses and IL-1Ra- IL-1R immune evasion strategies of emerging fungal pathogen Candida auris. PLoS Pathogens, 20(11). https://doi.org/10.1371/journal.ppat.1012699
8. Ball, B., Langille, M. G. I., & Geddes-McAlister, J. (2020). Fun(gi)omics: Advanced and Diverse Technologies to Explore Emerging Fungal Pathogens and Define Mechanisms of Antifungal Resistance [Review of Fun(gi)omics: Advanced and Diverse Technologies to Explore Emerging Fungal Pathogens and Define Mechanisms of Antifungal Resistance]. mBio, 11(5). American Society for Microbiology. https://doi.org/10.1128/mbio.01020-20
9. Bandara, N., & Samaranayake, L. P. (2022). Emerging and future strategies in the management of recalcitrant Candida auris [Review of Emerging and future strategies in the management of recalcitrant Candida auris]. Medical Mycology, 60(4). Oxford University Press. https://doi.org/10.1093/mmy/myac008
10. Bassey, E. E., Mohammed, G. A., Bala, H. M., Ogonna, U. S., Yawuri, B. B., & Maduchi, O. C. (2016). Phytochemical Analysis and Antimicrobial Activity of Methanolic, Ethanolic and Acetonic Extracts of Stem Bark and Leaf of Neem Plant (Azadirachta indica).
11. Beardsley, J., Halliday, C., Chen, S. C. -A., & Sorrell, T. C. (2018). Responding to the Emergence of Antifungal Drug Resistance: Perspectives from the Bench and the Bedside [Review of Responding to the Emergence of Antifungal Drug Resistance: Perspectives from the Bench and the

Bedside]. Future Microbiology, 13(10), 1175. Future Medicine. https://doi.org/10.2217/fmb-2018-0059

12. Benedict, K., Forsberg, K., Gold, J. A. W., Baggs, J., & Lyman, M. (2023). Candida auris–Associated Hospitalizations, United States, 2017–2022. Emerging Infectious Diseases, 29(7). https://doi.org/10.3201/eid2907.230540
13. Bhargava, A., Klamer, K., Sharma, M., Ortiz, D. A., & Saravolatz, L. (2025). Candida auris: A Continuing Threat [Review of Candida auris: A Continuing Threat]. Microorganisms, 13(3), 652. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/microorganisms13030652
14. Billamboz, M., Fatima, Z., Hameed, S., & Jawhara, S. (2021). Promising Drug Candidates and New Strategies for Fighting against the Emerging Superbug Candida auris [Review of Promising Drug Candidates and New Strategies for Fighting against the Emerging Superbug Candida auris]. Microorganisms, 9(3), 634. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/microorganisms9030634
15. Blackman, I., Riklikienė, O., Gurková, E., Willis, E., & Henderson, J. (2021). Predictors of missed infection control care: A tri-partite international study. Journal of Advanced Nursing, 78(2), 414. https://doi.org/10.1111/jan.14976
16. Boutin, C., & Luong, M. (2024). Update on therapeutic approaches for invasive fungal infections in adults. Therapeutic Advances in Infectious Disease, 11. https://doi.org/10.1177/20499361231224980
17. Brown, G. D. (2011). Innate Antifungal Immunity: The Key Role of Phagocytes [Review of Innate Antifungal Immunity: The Key Role of Phagocytes]. Annual Review of Immunology, 29(1), 1. Annual Reviews. https://doi.org/10.1146/annurev-immunol-030409-101229
18. Bruch, A., Kelani, A. A., & Blango, M. G. (2021). RNA-based therapeutics to treat human fungal infections [Review of RNA-based therapeutics to treat human fungal infections]. Trends in Microbiology, 30(5), 411. Elsevier BV. https://doi.org/10.1016/j.tim.2021.09.007
19. Burgess, T. B., Condliffe, A. M., & Elks, P. M. (2022). A Fun-Guide to Innate Immune Responses to Fungal Infections [Review of A Fun-Guide to Innate Immune Responses to Fungal Infections]. Journal of Fungi, 8(8), 805. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/jof8080805
20. Casadevall, A. (2018). Fungal Diseases in the 21st Century: The Near and Far Horizons. Pathogens and Immunity, 3(2), 183. https://doi.org/10.20411/pai.v3i2.249
21. Casadevall, A. (2022). Immunity to Invasive Fungal Diseases [Review of Immunity to Invasive Fungal Diseases]. Annual Review of Immunology, 40(1), 121. Annual Reviews. https://doi.org/10.1146/annurev-immunol-101220-034306
22. Černáková, L., Roudbary, M., Brás, S., Tafaj, S., & Rodrigues, C. F. (2021). Candida auris: A Quick Review on Identification, Current Treatments, and Challenges [Review of Candida auris: A Quick Review on Identification, Current Treatments, and Challenges]. International Journal of Molecular Sciences, 22(9), 4470. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/ijms22094470
23. Chabasse, D., Pihet, M., & Bouchara, J. (2009). Émergence de nouveaux champignons pathogènes en médecine : revue générale. Revue Francophone Des Laboratoires, 2009(416), 71. https://doi.org/10.1016/s1773-035x(09)70253-9
24. Citarasu, T. (2009). Herbal biomedicines: a new opportunity for aquaculture industry. Aquaculture International, 18(3), 403. https://doi.org/10.1007/s10499-009-9253-7
25. Das, D., Ganesh, S. M., Mishra, A., Netea, M. G., & Thangamani, S. (2025). The Emerging Fungal Pathogen Candida auris Induces IFNγ to Colonize the Skin. PLoS Pathogens, 21(4). https://doi.org/10.1371/journal.ppat.1013114

26. Denning, D. W. (2022). Antifungal drug resistance: an update. European Journal of Hospital Pharmacy, 29(2), 109. https://doi.org/10.1136/ejhpharm-2020-002604

27. Drummond, R. A., Gaffen, S. L., Hise, A. G., & Brown, G. D. (2014). Innate Defense against Fungal Pathogens [Review of Innate Defense against Fungal Pathogens]. Cold Spring Harbor Perspectives in Medicine, 5(6). Cold Spring Harbor Laboratory Press. https://doi.org/10.1101/cshperspect.a019620

28. Du, H., Bing, J., Hu, T., Ennis, C. L., Nobile, C. J., & Huang, G. (2020). Candida auris: Epidemiology, biology, antifungal resistance, and virulence [Review of Candida auris: Epidemiology, biology, antifungal resistance, and virulence]. PLoS Pathogens, 16(10). Public Library of Science. https://doi.org/10.1371/journal.ppat.1008921

29. Eix, E. F., & Nett, J. E. (2024). Candida auris: Epidemiology and Antifungal Strategy [Review of Candida auris: Epidemiology and Antifungal Strategy]. Annual Review of Medicine. Annual Reviews. https://doi.org/10.1146/annurev-med-061523-021233

30. Fisher, M. C., Alastruey-Izquierdo, A., Berman, J., Bicanic, T., Bignell, E., Bowyer, P., Bromley, M., Brüggemann, R. J. M., Garber, G., Cornely, O. A., Gurr, S. J., Harrison, T. S., Kuijper, E. J., Rhodes, J., Sheppard, D. C., Warris, A., White, P. L., Xu, J., Zwaan, B. J., & Verweij, P. E. (2022). Tackling the emerging threat of antifungal resistance to human health [Review of Tackling the emerging threat of antifungal resistance to human health]. Nature Reviews Microbiology, 20(9), 557. Nature Portfolio. https://doi.org/10.1038/s41579-022-00720-1

31. Gaetano, S. D., Midiri, A., Mancuso, G., Avola, M. G., & Biondo, C. (2024). Candida auris Outbreaks: Current Status and Future Perspectives. Microorganisms, 12(5), 927. https://doi.org/10.3390/microorganisms12050927

32. García-Bustos, V., Cabañero-Navalón, M. D., Ruiz-Saurí, A., Ruiz-Gaitán, A., Salavert, M., Tormo-Más, M. Á., & Pemán, J. (2021). What Do We Know about Candida auris? State of the Art, Knowledge Gaps, and Future Directions [Review of What Do We Know about Candida auris? State of the Art, Knowledge Gaps, and Future Directions]. Microorganisms, 9(10), 2177. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/microorganisms9102177

33. George, M. G., Gaitor, T. T., Cluck, D., Henao-Martínez, A. F., Sells, N. R., & Chastain, D. B. (2025). The impact of climate change on the epidemiology of fungal infections: implications for diagnosis, treatment, and public health strategies [Review of The impact of climate change on the epidemiology of fungal infections: implications for diagnosis, treatment, and public health strategies]. Therapeutic Advances in Infectious Disease, 12. SAGE Publishing. https://doi.org/10.1177/20499361251313841

34. Geremia, N., Brugnaro, P., Solinas, M., Scarparo, C., & Panese, S. (2023). Candida auris as an Emergent Public Health Problem: A Current Update on European Outbreaks and Cases [Review of Candida auris as an Emergent Public Health Problem: A Current Update on European Outbreaks and Cases]. Healthcare, 11(3), 425. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/healthcare11030425

35. Giacobbe, D. R., Mikulska, M., Vena, A., Pilato, V. D., Magnasco, L., Marchese, A., & Bassetti, M. (2023). Challenges in the diagnosis and treatment of candidemia due to multidrug-resistant Candida auris. Frontiers in Fungal Biology, 4. https://doi.org/10.3389/ffunb.2023.1061150

36. Gow, N. A. R., Johnson, C., Berman, J., Coste, A. T., Cuomo, C. A., Perlin, D. S., Bicanic, T., Harrison, T. S., Wiederhold, N. P., Bromley, M., Chiller, T., & Edgar, K. (2022). The importance of antimicrobial resistance in medical mycology [Review of The importance of antimicrobial resistance in medical mycology]. Nature Communications, 13(1). Nature Portfolio. https://doi.org/10.1038/s41467-022-32249-5

37. Griffith, N., & Danziger, L. H. (2020). Candida auris Urinary Tract Infections and Possible Treatment [Review of Candida auris Urinary Tract Infections and Possible Treatment]. Antibiotics,

9(12), 898. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/antibiotics9120898

38. Groll, A. H., & Walsh, T. J. (2001). Uncommon opportunistic fungi: new nosocomial threats [Review of Uncommon opportunistic fungi: new nosocomial threats]. Clinical Microbiology and Infection, 7, 8. Elsevier BV. https://doi.org/10.1111/j.1469-0691.2001.tb00005.x

39. Halili, M. L. M., & Sorensen, G. G. (2020). Incidence and Management of Candida Auris in a Skilled Nursing Home. American Journal of Infection Control, 48(8). https://doi.org/10.1016/j.ajic.2020.06.128

40. Harun, N. H., Septama, A. W., Ahmad, W. A. N. W., & Suppıan, R. (2019). The Potential of Centella asiatica (Linn.) Urban as an Anti-Microbial and Immunomodulator Agent: A Review [Review of The Potential of Centella asiatica (Linn.) Urban as an Anti-Microbial and Immunomodulator Agent: A Review]. Natural Product Sciences, 25(2), 92. Korean Society of Pharmacognosy. https://doi.org/10.20307/nps.2019.25.2.92

41. Hata, D. J., Humphries, R. M., & Lockhart, S. R. (2019). Candida auris: An Emerging Yeast Pathogen Posing Distinct Challenges for Laboratory Diagnostics, Treatment, and Infection Prevention [Review of Candida auris: An Emerging Yeast Pathogen Posing Distinct Challenges for Laboratory Diagnostics, Treatment, and Infection Prevention]. Archives of Pathology & Laboratory Medicine, 144(1), 107. American Medical Association. https://doi.org/10.5858/arpa.2018-0508-ra

42. Hayes, J. F. (2024). Candida auris: Epidemiology Update and a Review of Strategies to Prevent Spread [Review of Candida auris: Epidemiology Update and a Review of Strategies to Prevent Spread]. Journal of Clinical Medicine, 13(22), 6675. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/jcm13226675

43. Hennessee, I., Forsberg, K., Erskine, J., Charles, A., Russell, B. A., Reyes-Urueña, J., Emery, C., Valencia, N., Sherman, A., Mehr, J., Gallion, H., Halleck, B., Cox, C., Bryant, M., Nichols, D., Medrzycki, M., Ham, D. C., Hagan, L. M., & Lyman, M. (2024). Candida auris in US Correctional Facilities. Emerging Infectious Diseases, 30(13). https://doi.org/10.3201/eid3013.230860

44. Hetta, Helal F., Ramadan, Y. N., Al-Kadmy, I. M. S., Ellah, N. H. A., Shbibe, L., & Battah, B. (2023). Nanotechnology-Based Strategies to Combat Multidrug-Resistant Candida auris Infections [Review of Nanotechnology-Based Strategies to Combat Multidrug-Resistant Candida auris Infections]. Pathogens, 12(8), 1033. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/pathogens12081033

45. Hou, T., Bell, W. R., & Mesa, H. (2024). Invasive Fungal Infections of the Head and Neck: A Tertiary Hospital Experience. Pathogens, 13(7), 530. https://doi.org/10.3390/pathogens13070530

46. Hu, S., Zhu, F., Jiang, W., Wang, Y., Quan, Y., Zhang, G., Gu, F., & Yang, Y. (2021). Retrospective Analysis of the Clinical Characteristics of Candida auris Infection Worldwide From 2009 to 2020. Frontiers in Microbiology, 12. https://doi.org/10.3389/fmicb.2021.658329

47. Islam, T., Danishuddin, M., Tamanna, N. T., Matin, M. N., Barai, H. R., & Haque, M. A. (2024). Resistance Mechanisms of Plant Pathogenic Fungi to Fungicide, Environmental Impacts of Fungicides, and Sustainable Solutions [Review of Resistance Mechanisms of Plant Pathogenic Fungi to Fungicide, Environmental Impacts of Fungicides, and Sustainable Solutions]. Plants, 13(19), 2737. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/plants13192737

48. Jafarlou, M. (2024). Unveiling the menace: a thorough review of potential pandemic fungal disease [Review of Unveiling the menace: a thorough review of potential pandemic fungal disease]. Frontiers in Fungal Biology, 5. Frontiers Media. https://doi.org/10.3389/ffunb.2024.1338726

49. Jain, M., Jain, A., Khare, B., Jain, D. K., Khan, R., & Jain, D. (2022). An Update on the Recent Emergence of Candida auris. Asian Journal of Dental and Health Sciences, 2(1), 14. https://doi.org/10.22270/ajdhs.v2i1.11

50. Jong, A. W. de, & Hagen, F. (2019). Attack, Defend and Persist: How the Fungal Pathogen Candida auris was Able to Emerge Globally in Healthcare Environments [Review of Attack, Defend and Persist: How the Fungal Pathogen Candida auris was Able to Emerge Globally in Healthcare Environments]. Mycopathologia, 184(3), 353. Springer Science+Business Media. https://doi.org/10.1007/s11046-019-00351-w

51. Journal of Mycology and Infection. (2018). Journal of Mycology and Infection. https://doi.org/10.17966/jmi

52. Kappel, D., Gifford, H., Brackin, A. P., Abdolrasouli, A., Eyre, D. W., Jeffery, K., Schlenz, S., Aanensen, D. M., Brown, C., Borman, A. M., Johnson, E. M., Holmes, A., Armstrong-James, D., Fisher, M. C., & Rhodes, J. (2024). Genomic epidemiology describes introduction and outbreaks of antifungal drug-resistant Candida auris. Npj Antimicrobials and Resistance, 2(1). https://doi.org/10.1038/s44259-024-00043-6

53. Kean, R., Brown, J. L., Gülmez, D., Ware, A., & Ramage, G. (2020). Candida auris: A Decade of Understanding of an Enigmatic Pathogenic Yeast [Review of Candida auris: A Decade of Understanding of an Enigmatic Pathogenic Yeast]. Journal of Fungi, 6(1), 30. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/jof6010030

54. Kim, J.-S., Cha, H., & Bahn, Y. (2024). Comprehensive Overview of Candida auris: An Emerging Multidrug-Resistant Fungal Pathogen [Review of Comprehensive Overview of Candida auris: An Emerging Multidrug-Resistant Fungal Pathogen]. Journal of Microbiology and Biotechnology, 34(7), 1365. Springer Science+Business Media. https://doi.org/10.4014/jmb.2404.04040

55. Kurt, A., Kuşkucu, M. A., Balkan, Ii. I., Barış, A., Yazgan, Z., Oz, A. S., Tosun, A. İ., Mete, B., Tabak, F., & Aygün, G. (2021). Candida auris Fungemia and a local spread taken under control with infection control measures: First report from Turkey. Indian Journal of Medical Microbiology, 39(2), 228. https://doi.org/10.1016/j.ijmmb.2021.03.007

56. Lamps, L. W., Lai, K., & Milner, D. A. (2014). Fungal Infections of the Gastrointestinal Tract in the Immunocompromised Host [Review of Fungal Infections of the Gastrointestinal Tract in the Immunocompromised Host]. Advances in Anatomic Pathology, 21(4), 217. Lippincott Williams & Wilkins. https://doi.org/10.1097/pap.0000000000000016

57. León-Buitimea, A., Garza-Cervantes, J. A., Gallegos-Alvarado, D. Y., Osorio-Concepción, M., & Morones-Ramírez, J. R. (2021). Nanomaterial-Based Antifungal Therapies to Combat Fungal Diseases Aspergillosis, Coccidioidomycosis, Mucormycosis, and Candidiasis [Review of Nanomaterial-Based Antifungal Therapies to Combat Fungal Diseases Aspergillosis, Coccidioidomycosis, Mucormycosis, and Candidiasis]. Pathogens, 10(10), 1303. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/pathogens10101303

58. Lino, R., Guimarães, A. R., Sousa, E., Azevedo, M., & Santos, L. (2024). Emerging Fungal Infections of the Central Nervous System in the Past Decade: A Literature Review [Review of Emerging Fungal Infections of the Central Nervous System in the Past Decade: A Literature Review]. Infectious Disease Reports, 16(5), 952. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/idr16050076

59. Lionakis, M. S., Drummond, R. A., & Hohl, T. M. (2023). Immune responses to human fungal pathogens and therapeutic prospects [Review of Immune responses to human fungal pathogens and therapeutic prospects]. Nature Reviews. Immunology, 23(7), 433. Nature Portfolio. https://doi.org/10.1038/s41577-022-00826-w

60. Loh, J. T., & Lam, K. (2023). Fungal infections: Immune defense, immunotherapies and vaccines [Review of Fungal infections: Immune defense, immunotherapies and vaccines]. Advanced Drug Delivery Reviews, 196, 114775. Elsevier BV. https://doi.org/10.1016/j.addr.2023.114775

61. López-Vilella, R., Ruiz-Gaitán, A., Gimeno, R., Marqués-Sulé, E., Guillén, R. V., Pemán, J., Sánchez-Lázaro, I., & Bonet, L. A. (2018). Candida auris and Heart Transplantation. Preoperative Attitude. OBM Transplantation, 3(1), 1. https://doi.org/10.21926/obm.transplant.1901053

62. Lucy, A., Paula, G. R. de, ROVINSKI, C. A., & Jailan, O. (2022). Novel case of Candida auris in the Veterans Health Administration and in the state of South Carolina. American Journal of Infection Control, 50(11), 1258. https://doi.org/10.1016/j.ajic.2022.05.020

63. Mallick, D., Kaushik, N., Goyal, L., Mallick, L., & Singh, P. (2025). A Comprehensive Review of Candidemia and Invasive Candidiasis in Adults: Focus on the Emerging Multidrug-Resistant Fungus Candida auris [Review of A Comprehensive Review of Candidemia and Invasive Candidiasis in Adults: Focus on the Emerging Multidrug-Resistant Fungus Candida auris]. Diseases, 13(4), 93. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/diseases13040093

64. Mandal, P., Upadhyay, S. K., Poudyal, B., & Sampagavi, M. (2021). Formulation and evaluation of herbal paper soap.

65. Melo, W. C. de, Scorzoni, L., Rossi, S. A., Orlandi, C. B. C., Yonashiro, M., Mendes-Giannini, M. J. S., & Fusco-Almeida, A. M. (2017). Update on Fungal Disease: From Establish Infection to Clinical Manifestation. Journal of Biotechnology & Biomaterials, 7(3). https://doi.org/10.4172/2155-952x.1000273

66. Mirabet, V., Artigues, E., Galán, J. C., Escobedo-Lucea, C., Larrea, L., Arbona, C., Gimeno, C., & Pemán, J. (2020). Contamination of tissue allografts from a multiorgan-multitissue donor colonized by Candida auris. Transplant Infectious Disease, 23(3). https://doi.org/10.1111/tid.13535

67. Mishra, S. K., Yasir, M., & Willcox, M. (2023). Candida auris: an emerging antimicrobial-resistant organism with the highest level of concern. The Lancet Microbe, 4(7). https://doi.org/10.1016/s2666-5247(23)00114-3

68. Money, N. P. (2024). Fungal thermotolerance revisited and why climate change is unlikely to be supercharging pathogenic fungi (yet). Fungal Biology, 128(1), 1638. https://doi.org/10.1016/j.funbio.2024.01.005

69. Moore, R., Lie, L., Pua, H., Slade, D. H., Rangel, S., Davila, A., Carson, J., & Parada, J. P. (2022). 1225. The Perfect Storm: A Hardy and Lethal Pathogen and a Unit Filled with Immunocompromised Patients with Large Open Wounds. Troubles with Candida Auris in a Burn Intensive Care Unit. Open Forum Infectious Diseases, 9. https://doi.org/10.1093/ofid/ofac492.1057

70. Niño-Vega, G. A., Padró-Villegas, L., & López-Romero, E. (2024). New Ground in Antifungal Discovery and Therapy for Invasive Fungal Infections: Innovations, Challenges, and Future Directions [Review of New Ground in Antifungal Discovery and Therapy for Invasive Fungal Infections: Innovations, Challenges, and Future Directions]. Journal of Fungi, 10(12), 871. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/jof10120871

71. Omardien, S., & Teska, P. J. (2024). Skin and hard surface disinfection against Candida auris – What we know today. Frontiers in Medicine, 11. https://doi.org/10.3389/fmed.2024.1312929

72. Posteraro, B., Torelli, R., Carolis, E. D., Posteraro, P., & Sanguinetti, M. (2014). Antifungal Susceptibility Testing: Current Role from the Clinical Laboratory Perspective, Review of Antifungal Susceptibility Testing: Current Role from the Clinical Laboratory Perspective. Mediterranean Journal of Hematology and Infectious Diseases, 6(1). PAGE Press (Italy). https://doi.org/10.4084/mjhid.2014.030

73. Retanal, C., Ball, B., & Geddes-McAlister, J. (2021). Post-Translational Modifications Drive Success and Failure of Fungal–Host Interactions [Review of Post-Translational Modifications Drive Success and Failure of Fungal–Host Interactions]. Journal of Fungi, 7(2), 124. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/jof7020124

74. Riley, M. M.-S. (2021). Invasive Fungal Infections Among Immunocompromised Patients in Critical Care Settings [Review of Invasive Fungal Infections Among Immunocompromised Patients in Critical Care Settings]. Critical Care Nursing Clinics of North America, 33(4), 395. Elsevier BV. https://doi.org/10.1016/j.cnc.2021.07.002

75. Ruchti, F., & LeibundGut-Landmann, S. (2022). New insights into immunity to skin fungi shape our understanding of health and disease [Review of New insights into immunity to skin fungi shape our understanding of health and disease]. Parasite Immunology, 45(2). Wiley. https://doi.org/10.1111/pim.12948

76. Rybak, J. M., Barker, K. S., Muñoz, J. F., Parker, J. E., Ahmad, S., Mokaddas, E., Abdullah, A. A., Elhagracy, R. S., Kelly, S. L., Cuomo, C. A., & Rogers, P. D. (2021). In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin B resistance in Candida auris. Clinical Microbiology and Infection, 28(6), 838. https://doi.org/10.1016/j.cmi.2021.11.024

77. Sabino, R., Veríssimo, C., Pereira, Á., & Antunes, F. (2020). Candida Auris, An Agent of Hospital-Associated Outbreaks: Which Challenging Issues Do We Need to Have in Mind? [Review of Candida Auris, An Agent of Hospital-Associated Outbreaks: Which Challenging Issues Do We Need to Have in Mind?]. Microorganisms, 8(2), 181. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/microorganisms8020181

78. Sansom, S. E., Gussin, G., Singh, R., Bell, P., Benson, E. C., Makhija, J., Froilan, M. C., Saavedra, R., Pedroza, R., Thotapalli, L., Fukuda, C., Gough, E., Rodriguez, S. M., Guzman, M. del M. V., Shimabukuro, J. A., Mikhail, L., Black, S., Pacilli, M., Adil, H., … Hayden, M. K. (2022). 88. Increasing Bioburden of Candida auris Body Site Colonization is Associated with Environmental Contamination. Open Forum Infectious Diseases, 9. https://doi.org/10.1093/ofid/ofac492.013

79. Sanyaolu, A., Okorie, C., Marinkovic, A., Abbasi, A. F., Prakash, S., Mangat, J., Hosein, Z., Haider, N., & Chan, J. (2022). Candida auris: An Overview of the Emerging Drug-Resistant Fungal Infection [Review of Candida auris: An Overview of the Emerging Drug-Resistant Fungal Infection]. Infection and Chemotherapy, 54(2), 236. Jin Publishing & Printing Co. https://doi.org/10.3947/ic.2022.0008

80. Sathyapalan, D. T., Antony, R., Nampoothiri, V., Kumar, A., Shashindran, N., James, J., Thomas, J., Prasanna, P., Sudhir, A. S., Philip, J. M., Edathadathil, F., Prabhu, B., Singh, S., & Moni, M. (2021). Evaluating the measures taken to contain a Candida auris outbreak in a tertiary care hospital in South India: an outbreak investigational study. BMC Infectious Diseases, 21(1). https://doi.org/10.1186/s12879-021-06131-6

81. Seidel, D., Wurster, S., Jenks, J. D., Sati, H., Gangneux, J., Egger, M., Alastruey-Izquierdo, A., Ford, N., Chowdhary, A., Sprute, R., Cornely, O. A., Thompson, G. R., Hoenigl, M., & Kontoyiannis, D. P. (2024). Impact of climate change and natural disasters on fungal infections [Review of Impact of climate change and natural disasters on fungal infections]. The Lancet Microbe, 5(6). Elsevier BV. https://doi.org/10.1016/s2666-5247(24)00039-9

82. Shinn, A. P., & Bron, J. E. (2012). Considerations for the use of anti-parasitic drugs in aquaculture. In Elsevier eBooks (p. 190). Elsevier BV. https://doi.org/10.1533/9780857095732.2.190

83. Sigera, L., Jayawardena, M. D. S., Thabrew, H., & Jayasekera, P. (2020). Candida auris: A brief review [Review of Candida auris: A brief review]. Sri Lankan Journal of Infectious Diseases, 10(1), 2. Sri Lankan Society for Microbiology. https://doi.org/10.4038/sljid.v10i1.8270

84. Spivak, E. S., & Hanson, K. E. (2017). Candida auris: an Emerging Fungal Pathogen [Review of Candida auris: an Emerging Fungal Pathogen]. Journal of Clinical Microbiology, 56(2). American Society for Microbiology. https://doi.org/10.1128/jcm.01588-17

85. Srinivasan, A., López-Ribot, J. L., & Ramasubramanian, A. K. (2014). Overcoming antifungal resistance [Review of Overcoming antifungal resistance]. Drug Discovery Today Technologies, 11, 65. Elsevier BV. https://doi.org/10.1016/j.ddtec.2014.02.005

86. Stanciu, A., Florea, D., Surleac, M., Paraschiv, S., Oţelea, D., Tălăpan, D., & Popescu, G. A. (2023). First report of Candida auris in Romania: clinical and molecular aspects. Antimicrobial Resistance and Infection Control, 12(1). https://doi.org/10.1186/s13756-023-01297-x

87. Sticchi, C., Raso, R., Ferrara, L., Vecchi, E. D., Ferrero, L., Filippi, D., Finotto, G., Frassinelli, E., Silvestre, C., Zozzoli, S., Ambretti, S., Diegoli, G., Gagliotti, C., Moro, M. L., Ricchizzi, E., Tumietto, F., Russo, F., Tonon, M., Maraglino, F., … Sabbatucci, M. (2023). Increasing Number of Cases Due to Candida auris in North Italy, July 2019–December 2022. Journal of Clinical Medicine, 12(5), 1912. https://doi.org/10.3390/jcm12051912

88. Tu, J., Liu, N., Huang, Y., Yang, W., & Sheng, C. (2022). Small molecules for combating multidrug-resistant superbug Candida auris infections [Review of Small molecules for combating multidrug-resistant superbug Candida auris infections]. Acta Pharmaceutica Sinica B, 12(11), 4056. Elsevier BV. https://doi.org/10.1016/j.apsb.2022.08.001

89. Wang, F., Han, R., & Chen, S. (2025). Initiatives and approaches for antifungal research. The Innovation Medicine, 100116. https://doi.org/10.59717/j.xinn-med.2025.100116

90. Wang, S., Pan, J., Gu, L., Wang, W., Wei, B., Zhang, H., Chen, J., & Wang, H. (2023). Review of treatment options for a multidrug-resistant fungus: Candida auris. Medical Mycology, 62(1). https://doi.org/10.1093/mmy/myad127

91. Wang, Y., Zou, Y., Chen, X., Li, H., Yin, Z., Zhang, B., Xu, Y., Zhang, Y., Zhang, R., Huang, X., Yang, W., Xu, C., Jiang, T., Tang, Q., Zhou, Z., Ji, Y., Liu, Y., Hu, L., Zhou, J., … Zhou, D. (2022). Innate immune responses against the fungal pathogen Candida auris. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-31201-x

92. Watkins, R., Gowen, R., Lionakis, M. S., & Ghannoum, M. A. (2022). Update on the Pathogenesis, Virulence, and Treatment of Candida auris [Review of Update on the Pathogenesis, Virulence, and Treatment of Candida auris]. Pathogens and Immunity, 7(2), 46. Case Western Reserve University. https://doi.org/10.20411/pai.v7i2.535

93. Yune, P. S., Coe, J., Rao, M., & Lin, M. Y. (2023). Candida auris in skilled nursing facilities [Review of Candida auris in skilled nursing facilities]. Therapeutic Advances in Infectious Disease, 10. SAGE Publishing. https://doi.org/10.1177/20499361231189958